Andrew C Schofield
Overview
Explore the profile of Andrew C Schofield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kastl L, Brown I, Schofield A
Int J Oncol
. 2010 Apr;
36(5):1235-41.
PMID: 20372798
Docetaxel is an effective chemotherapy drug to treat breast cancer but the underlying molecular mechanisms of drug resistance are not fully understood. DNA methylation is an epigenetic event, involved in...
2.
Kastl L, Brown I, Schofield A
Mol Cell Probes
. 2009 Oct;
24(2):87-92.
PMID: 19837153
To quantify gene expression levels, appropriate controls have to be used to adjust for experimental variation. Endogenous control genes are widely used as they are stably expressed independent of cell...
3.
Brown I, Halliday S, Greig H, Heys S, Wallace H, Schofield A
Fam Cancer
. 2009 Feb;
8(4):307-11.
PMID: 19225907
Ornithine decarboxylase (ODC), the first enzyme in the biosynthesis of polyamines, has increased activity in breast cancer tissue compared with benign and normal tissues. The ODC gene contains a single...
4.
Nanthakumaran S, Brown I, Heys S, Schofield A
Clin Nutr
. 2008 Nov;
28(1):65-70.
PMID: 19036482
Background & Aims: Immunonutrition, containing arginine as a key component, has been shown to enhance the immune system and significantly reduce infectious complications in patients undergoing upper gastrointestinal surgery. Arginine,...
5.
Shaikh I, Brown I, Schofield A, Wahle K, Heys S
Prostate
. 2008 Aug;
68(15):1635-46.
PMID: 18668525
Background: Evidence is growing for beneficial interactions between omega-3 fatty acids from fish and chemotherapy agents in certain human cancers. Evidence for similar effects in prostate cancer is lacking. We...
6.
Fite A, Goua M, Wahle K, Schofield A, Hutcheon A, Heys S
Prostaglandins Leukot Essent Fatty Acids
. 2007 Sep;
77(2):87-96.
PMID: 17900885
Response rates of tumours to docetaxel (DOCT) are 45-60% in advanced breast cancer but problems associated with side effects, drug resistance and high costs occur. Conjugated linoleic acids (CLAs) also...
7.
Chaturvedi S, McLaren C, Schofield A, Ogston K, Sarkar T, Hutcheon A, et al.
Breast Cancer Res Treat
. 2005 Sep;
93(2):151-8.
PMID: 16187235
This study aimed to evaluate patterns of local and distant disease recurrence in patients having primary chemotherapy and compared patterns of relapse in patients with a complete pathological response with...
8.
Shalli K, Brown I, Heys S, Schofield A
FASEB J
. 2005 Jun;
19(10):1299-301.
PMID: 15946994
Docetaxel is one of the most active drugs used to treat breast cancer. The cellular target of docetaxel is the microtubule, specifically the beta-tubulin subunit, that comprises a series of...
9.
McDonald S, Stevenson D, Moir S, Hutcheon A, Haites N, Heys S, et al.
Eur J Cancer
. 2005 May;
41(7):1086-94.
PMID: 15862759
Docetaxel is one of the most effective chemotherapeutic agents in the treatment of breast cancer. Breast cancers can have an inherent or acquired resistance to docetaxel but the causes of...
10.
Ogston K, Miller I, Schofield A, Spyrantis A, Pavlidou E, Sarkar T, et al.
Breast Cancer Res Treat
. 2004 Aug;
86(2):181-9.
PMID: 15319570
Purpose: Primary chemotherapy is commonly used in patients with breast cancer to downstage the primary tumour prior to surgery. There is a need to establish, prior to commencement of chemotherapy,...